494 related articles for article (PubMed ID: 18977345)
1. KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups.
Sritana N; Auewarakul CU
Exp Mol Pathol; 2008 Dec; 85(3):227-31. PubMed ID: 18977345
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of tyrosine kinases gene mutations in core binding factor related acute myeloid leukemia and its clinical significance].
Qiao M; Li WY; Sun AN; Chen SN; Liang JY; Ding ZX; Feng YF; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2011 Oct; 32(10):679-83. PubMed ID: 22339826
[TBL] [Abstract][Full Text] [Related]
3. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
4. FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
Goemans BF; Zwaan CM; Cloos J; de Lange D; Loonen AH; Reinhardt D; Hählen K; Gibson BE; Creutzig U; Kaspers GJ
Leuk Res; 2010 Oct; 34(10):1302-7. PubMed ID: 20435347
[TBL] [Abstract][Full Text] [Related]
5. Analysis of FLT3-ITD and FLT3-Asp835 mutations in de novo acute myeloid leukemia: evaluation of incidence, distribution pattern, correlation with cytogenetics and characterization of internal tandem duplication from Indian population.
Ahmad F; Mandava S; Das BR
Cancer Invest; 2010 Jan; 28(1):63-73. PubMed ID: 19995225
[TBL] [Abstract][Full Text] [Related]
6. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.
Beghini A; Ripamonti CB; Cairoli R; Cazzaniga G; Colapietro P; Elice F; Nadali G; Grillo G; Haas OA; Biondi A; Morra E; Larizza L
Haematologica; 2004 Aug; 89(8):920-5. PubMed ID: 15339674
[TBL] [Abstract][Full Text] [Related]
7. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML).
Boissel N; Leroy H; Brethon B; Philippe N; de Botton S; Auvrignon A; Raffoux E; Leblanc T; Thomas X; Hermine O; Quesnel B; Baruchel A; Leverger G; Dombret H; Preudhomme C; ;
Leukemia; 2006 Jun; 20(6):965-70. PubMed ID: 16598313
[TBL] [Abstract][Full Text] [Related]
8. Detection of KIT and FLT3 mutations in acute myeloid leukemia with different subtypes.
Zaker F; Mohammadzadeh M; Mohammadi M
Arch Iran Med; 2010 Jan; 13(1):21-5. PubMed ID: 20039765
[TBL] [Abstract][Full Text] [Related]
9. RAS, FLT3, and C-KIT mutations in immunophenotyped canine leukemias.
Usher SG; Radford AD; Villiers EJ; Blackwood L
Exp Hematol; 2009 Jan; 37(1):65-77. PubMed ID: 18977066
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in AML in relation to (ab)normal karyotype.
Stone RM
Best Pract Res Clin Haematol; 2009 Dec; 22(4):523-8. PubMed ID: 19959103
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of cooperative gene mutations between class I and class II in de novo acute myeloid leukemia.
Ishikawa Y; Kiyoi H; Tsujimura A; Miyawaki S; Miyazaki Y; Kuriyama K; Tomonaga M; Naoe T
Eur J Haematol; 2009 Aug; 83(2):90-8. PubMed ID: 19309322
[TBL] [Abstract][Full Text] [Related]
12. Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3.
Smith ML; Arch R; Smith LL; Bainton N; Neat M; Taylor C; Bonnet D; Cavenagh JD; Andrew Lister T; Fitzgibbon J
Br J Haematol; 2005 Feb; 128(3):318-23. PubMed ID: 15667533
[TBL] [Abstract][Full Text] [Related]
13. NPM1, FLT3, and c-KIT mutations in pediatric acute myeloid leukemia in Russian population.
Yatsenko Y; Kalennik O; Maschan M; Kalinina I; Maschan A; Nasedkina T
J Pediatr Hematol Oncol; 2013 Apr; 35(3):e100-8. PubMed ID: 23511494
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia.
De J; Zanjani R; Hibbard M; Davis BH
Am J Clin Pathol; 2007 Oct; 128(4):550-7. PubMed ID: 17875504
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3.
Masson K; Rönnstrand L
Cell Signal; 2009 Dec; 21(12):1717-26. PubMed ID: 19540337
[TBL] [Abstract][Full Text] [Related]
16. Prospective study of 174 de novo acute myelogenous leukemias according to the WHO classification: subtypes, cytogenetic features and FLT3 mutations.
Bao L; Wang X; Ryder J; Ji M; Chen Y; Chen H; Sun H; Yang Y; Du X; Kerzic P; Gross SA; Yao L; Lv L; Fu H; Lin G; Irons RD
Eur J Haematol; 2006 Jul; 77(1):35-45. PubMed ID: 16573742
[TBL] [Abstract][Full Text] [Related]
17. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
Wang LH; Wang M; Zhou CL; Chen S; Zhang XW; Xing HY; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
[TBL] [Abstract][Full Text] [Related]
18. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
[TBL] [Abstract][Full Text] [Related]
19. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
Neben K; Schnittger S; Brors B; Tews B; Kokocinski F; Haferlach T; Müller J; Hahn M; Hiddemann W; Eils R; Lichter P; Schoch C
Oncogene; 2005 Feb; 24(9):1580-8. PubMed ID: 15674343
[TBL] [Abstract][Full Text] [Related]
20. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
